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In the years before human immunodeficiency virus (HIV) infection, the incidence of Kaposi’s sarcoma varied markedly across the
African continent, and it was a disease primarily affecting men. In contrast, the evidence reviewed here shows that the causal virus–
Kaposi’s sarcoma associated herpesvirus (KSHV)–is prevalent in many African countries, including places where Kaposi’s sarcoma was
almost unknown before HIV, and that it is as common in women as in men. Therefore, the geographical distribution of Kaposi’s
sarcoma in Africa before the spread of HIV and its predominance as a disease affecting men are not a simple reflection of the
distribution of KSHV. Since the epidemic of HIV in Africa, Kaposi’s sarcoma has become relatively more frequent in women, and the
incidence has increased in countries where it was previously rare, but where KSHV is prevalent, as well as in countries where it was
already common. These changes point to a role for other (as yet unknown) factors in the aetiology of Kaposi’s sarcoma that may have
the most effect in the absence of concurrent HIV infection.
British Journal of Cancer (2003) 88, 1–3 doi:10.1038/sj.bjc.6600745 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: KSHV/HHV-8; Kaposi’s sarcoma; Africa
                                       
Before the human immunodeficiency virus (HIV) epidemic,
Kaposi’s sarcoma had a much greater geographical variation in
incidence than most other malignancies. It was as common in
parts of sub-Saharan Africa, such as Uganda, as colon cancer is in
Europe and the USA, representing up to 9% of all cancers in men
(Oettle ´, 1962; D’Oliveira and Torres, 1972; Templeton, 1981; Hutt,
1984; Cook-Mozaffari et al, 1998). Kaposi’s sarcoma was also
endemic, although much rarer, in counties around the Mediterra-
nean, particularly in Italy, Greece and the Middle East, but was
almost nonexistent elsewhere, except in immigrants from these
endemic countries (Biggar et al, 1984; Grulich et al, 1992; Hjalgrim
et al, 1996). The pattern of geographical variation in incidence
correlates broadly with the worldwide distribution of Kaposi’s
sarcoma-associated herpesvirus (KSHV; human herpesvirus-8
(HHV-8)), which is considered to be a necessary cause of Kaposi’s
sarcoma (Chang et al, 1994, 1996; Gao et al, 1996; Simpson et al;
1996; Boshoff, 1999). Here, we review published data on the
prevalence of infection with KSHV across Africa and make
comparison with the distribution of Kaposi’s sarcoma before and
since the start of the HIV epidemic.
METHODS
Studies published up to the end of March 2002 that looked for
evidence of infection with KSHV among people living in Africa
were identified through a Medline search, supplemented by an
examination of references given in identified papers and by
searching the index of relevant journals. No restriction was placed
on the language of publication, and foreign language papers were
translated. Only peer-reviewed journals were considered and no
attempt was made to identify unpublished studies or to obtain
unpublished data from published studies. Conference abstracts,
which are often based on preliminary analyses, were excluded. We
adopted the criteria that had been used within individual studies
for evidence of KSHV infection. Many of the identified studies
supplied prevalence estimates for children and adults, or estimates
derived from the use of more than one KSHV assay–the full range
of available estimates are shown in Table 1. Cumulative incidence
(for ages 0–64) of Kaposi’s sarcoma in men, prior to 1980, was
obtained from a published report by Cook-Mozaffari et al (1998).
Where regional rates within a given country were available, they
were used to calculate a country-wide mean incidence rate. Brief
details of the assays used in each study are included in the footnote
to the table, but this report is not intended as a review of methods
of detection of KSHV infection.
RESULTS AND DISCUSSION
In all, we identified 28 studies that had measured the prevalence of
KSHV infection in 16 African countries. Of these, three studies
identified evidence of KSHV-DNA in peripheral blood cells (Chang
et al, 1996; Kasolo et al, 1997; Belec et al, 1998), two used a lytic
antibody assay alone (He et al, 1998; Lampinen et al, 2000), five
used a latent antibody assay alone (Gao et al, 1996; Ariyoshi et al,
1998; Bestetti et al, 1998; Bourboulia et al, 1998; Sitas et al, 1999)
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Simpson et al, 1996; Mayama et al, 1998; Olsen et al, 1988; de The ´
et al, 1999; Ablashi et al, 1999; Andreoni et al, 1999, 2002; Enbom
et al, 1999; Gessain et al, 1999; Wilkinson et al, 1999; Engels et al,
2000; Rezza et al, 2000; Gaye Serraino-Diallo et al, 2001; Kakoola
et al, 2001; Nuvor et al, 2001; Serraino et al, 2001; Wawer et al,
2001). The results are presented in Table 1, together with the
estimated cumulative incidence of Kaposi’s sarcoma in men aged
0–64 years in the period before HIV infection (Cook-Mozaffari
et al, 1998).
KSHV is common in countries such as Uganda and Cameroon,
where Kaposi’s sarcoma was relatively frequent, but the virus is
also common in countries such as Botswana and the Gambia,
where Kaposi’s sarcoma rarely occurred before the spread of HIV
infection. There was no evidence in any of the studies that the
prevalence of KSHV (however it was measured) differed between
men and women. Before the onset of the HIV epidemic in the
1980s, Kaposi’s sarcoma showed extreme geographical variation in
incidence even within the African continent. Narrow belts of
relatively high incidence stretched westward across the former
Zaire to the coast of Cameroon and southward down the rift valley
to Malawi. In all of these areas, Kaposi’s sarcoma was more
common in men than in women (Cook-Mozaffari et al, 1998).
There is no evidence that the prevalence of KSHV has changed
in Africa since the spread of HIV. Indeed, KSHV, a g2 herpesvirus,
is thought to have coexisted alongside Homo sapiens since their
origin (reviewed by Hayward, 1999). Furthermore, the study by de
The ´ et al (1999) has shown that anti-KSHV antibodies were present
in Africa prior to the HIV epidemic at levels similar to those seen
today. Why then, was Kaposi’s sarcoma not more common in
African countries that have a high prevalence of KSHV and why,
when the virus is equally prevalent in men as it is in women, was
Kaposi’s sarcoma so much more frequent in men? Both anomalies
suggest the importance of further (as yet unknown) cofactors in
the aetiology of the tumour.
Parts of Africa with a high prevalence of HIV and where
Kaposi’s sarcoma was relatively common even in the years before
acquired immunodeficiency syndrome (AIDS) have seen an
explosion in the incidence of the tumour. In the last 10–15 years,
the incidence of Kaposi’s sarcoma has increased about 20-fold in
Uganda and Zimbabwe, such that it is now the most common
cancer in men and the second most common in women (Wabinga
et al, 1993, 2000; Bassett et al, 1995). As a result of the HIV
epidemic, the incidence of Kaposi’s sarcoma has also increased in
countries where it was previously relatively rare, but where KSHV
was prevalent. For example, between 1988 and 1996, the incidence
of Kaposi’s sarcoma has risen at least three-fold in South Africa
and continues to increase as the HIV epidemic grows. Data from
Johannesburg, South Africa, show that incidence rates of Kaposi’s
sarcoma have doubled in men, but have increased seven-fold in
women, such that the sex ratio of 7:1 in males vs females in 1988
has now declined to only 2:1 (Sitas and Newton, 2000). The role of
other cofactors in the aetiology of Kaposi’s sarcoma may,
therefore, be less relevant in the presence of HIV infection than
they seem to have been for the development of classical Kaposi’s
sarcoma prior to the spread of HIV.
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